Table of Contents
ISRN Inflammation
Volume 2012, Article ID 953461, 18 pages
http://dx.doi.org/10.5402/2012/953461
Review Article

Acute Phase Reactants as Novel Predictors of Cardiovascular Disease

1Department of Medicine, Royal University Hospital, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, Canada S7N 5E5
2Department of Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, Canada S7N 5E5
3Department of Pathology and Laboratory Medicine, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, Canada S7N 0W8

Received 27 January 2012; Accepted 1 April 2012

Academic Editors: N. Ortego-Centeno and S. Pender

Copyright © 2012 M. S. Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Tillett and T. Francis, “Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus,” The Journal of Experimental Medicine, vol. 52, pp. 561–567, 1930. View at Google Scholar
  2. A. S. Whitehead, G. A. P. Bruns, and A. F. Markham, “Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1,” Science, vol. 221, no. 4605, pp. 69–71, 1983. View at Google Scholar · View at Scopus
  3. E. B. Oliveira, E. C. Gotschlich, and T. Y. Liu, “Primary structure of human C-reactive protein,” The Journal of Biological Chemistry, vol. 254, no. 2, pp. 489–502, 1979. View at Google Scholar · View at Scopus
  4. P. A. Kavsak, A. R. MacRae, A. M. Newman et al., “Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure,” Clinical Biochemistry, vol. 40, no. 5-6, pp. 326–329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Vigushin, M. B. Pepys, and P. N. Hawkins, “Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1351–1357, 1993. View at Google Scholar · View at Scopus
  7. H. Yu and N. Rifai, “High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy,” Clinical Biochemistry, vol. 33, no. 8, pp. 601–610, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. T. P. Zwaka, V. Hombach, and J. Torzewski, “C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis,” Circulation, vol. 103, no. 9, pp. 1194–1197, 2001. View at Google Scholar · View at Scopus
  10. V. Pasceri, J. Chang, J. T. Willerson, and E. T. H. Yeh, “Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs,” Circulation, vol. 103, no. 21, pp. 2531–2534, 2001. View at Google Scholar · View at Scopus
  11. K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Generation of C-reactive protein and complement components in atherosclerotic plaques,” American Journal of Pathology, vol. 158, no. 3, pp. 1039–1051, 2001. View at Google Scholar · View at Scopus
  12. B. C. Berk, W. S. Weintraub, and R. W. Alexander, “Elevation of C-reactive protein in “active” coronary artery disease,” American Journal of Cardiology, vol. 65, no. 3, pp. 168–172, 1990. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Braunwald, “Unstable angina: an etiologic approach to management,” Circulation, vol. 98, no. 21, pp. 2219–2222, 1998. View at Google Scholar · View at Scopus
  14. M. Cesari, B. W. J. H. Penninx, A. B. Newman et al., “Inflammatory markers and onset of cardiovascular events: results from the health ABC study,” Circulation, vol. 108, no. 19, pp. 2317–2322, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Blake and P. M. Ridker, “C-reactive protein and other inflammatory risk markers in acute coronary syndromes,” Journal of the American College of Cardiology, vol. 41, no. 4, supplement, pp. 37S–42S, 2003. View at Google Scholar · View at Scopus
  16. C. Heeschen, C. W. Hamm, J. Bruemmer, and M. L. Simoons, “Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis,” Journal of the American College of Cardiology, vol. 35, no. 6, pp. 1535–1542, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. F. C. De Beer, C. R K Hind, K. M. Fox, R. M. Allan, A. Maseri, and M. B. Pepys, “Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction,” British Heart Journal, vol. 47, no. 3, pp. 239–243, 1982. View at Google Scholar · View at Scopus
  18. K. Pietilä, A. Harmoinen, L. Pöyhönen, M. Koskinen, J. Heikkila, and R. Ruosteenoja, “Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction,” British Heart Journal, vol. 58, no. 3, pp. 225–229, 1987. View at Google Scholar · View at Scopus
  19. S. Ueda, U. Ikeda, and K. Yamamoto, “C-reactive protein and complement in myocardial infarction and postinfarction heart failure,” European Heart Journal, vol. 18, no. 11, pp. 1834–1837, 1997. View at Google Scholar
  20. T. Anzai, T. Yoshikawa, H. Shiraki et al., “C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction,” Circulation, vol. 96, no. 3, pp. 778–784, 1997. View at Google Scholar · View at Scopus
  21. H. Toss, B. Lindahl, A. Siegbahn, and L. Wallentin, “Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease,” Circulation, vol. 96, no. 12, pp. 4204–4210, 1997. View at Google Scholar · View at Scopus
  22. S. K. James, P. Armstrong, E. Barnathan et al., “Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a. GUSTO-IV Substudy,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 916–924, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, and L. Wallentin, “Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease,” The New England Journal of Medicine, vol. 343, no. 16, pp. 1139–1147, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. James, B. Lindahl, A. Siegbahn et al., “N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy,” Circulation, vol. 108, no. 3, pp. 275–281, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Suleiman, R. Khatib, Y. Agmon et al., “Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: predictive role of C-reactive protein,” Journal of the American College of Cardiology, vol. 47, no. 5, pp. 962–968, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Mueller, H. J. Buettner, J. M. Hodgson et al., “Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients,” Circulation, vol. 105, no. 12, pp. 1412–1415, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. B. Pepys, “C-reactive protein fifty years on,” The Lancet, vol. 1, no. 8221, pp. 653–657, 1981. View at Google Scholar · View at Scopus
  29. P. M. Ridker, “High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention,” The American journal of cardiology, vol. 92, no. 4 B, 2003. View at Google Scholar · View at Scopus
  30. R. S. Schwartz, A. Bayes-Genis, J. R. Lesser, M. Sangiorgi, T. D. Henry, and C. A. Conover, “Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers,” Journal of Interventional Cardiology, vol. 16, no. 3, pp. 231–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Balk, J. Lau, L. C. Goudas et al., “Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review,” Annals of Internal Medicine, vol. 139, no. 8, pp. 670–682, 2003. View at Google Scholar · View at Scopus
  32. T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Festa, A. J. G. Hanley, R. P. Tracy, R. D'Agostino, and S. M. Haffner, “Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion,” Circulation, vol. 108, no. 15, pp. 1822–1830, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. T. B. Ledue, D. L. Weiner, J. D. Sipe, S. E. Poulin, M. F. Collins, and N. Rifai, “Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum,” Annals of Clinical Biochemistry, vol. 35, no. 6, pp. 745–753, 1998. View at Google Scholar · View at Scopus
  35. T. B. Ledue and N. Rifai, “Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment,” Clinical Chemistry, vol. 49, no. 8, pp. 1258–1271, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. I. S. Ockene, C. E. Matthews, N. Rifai, P. M. Ridker, G. Reed, and E. Stanek, “Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults,” Clinical Chemistry, vol. 47, no. 3, pp. 444–450, 2001. View at Google Scholar · View at Scopus
  38. L. M. Biasucci, G. Liuzzo, R. L. Grillo et al., “Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability,” Circulation, vol. 99, no. 7, pp. 855–860, 1999. View at Google Scholar · View at Scopus
  39. I. Kushner, M. L. Broder, and D. Karp, “Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction,” Journal of Clinical Investigation, vol. 61, no. 2, pp. 235–242, 1978. View at Google Scholar · View at Scopus
  40. K. O. Pietilä, A. P. Harmoinen, J. Jokiniitty, and A. I. Pasternack, “Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment,” European Heart Journal, vol. 17, no. 9, pp. 1345–1349, 1996. View at Google Scholar · View at Scopus
  41. V. B. Patel, M. A. Robbins, and E. J. Topol, “C-reactive protein: a “golden marker” for inflammation and coronary artery disease,” Cleveland Clinic Journal of Medicine, vol. 68, no. 6, pp. 521–534, 2001. View at Google Scholar · View at Scopus
  42. W. Koenig, M. Sund, M. Fröhlich et al., “C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992,” Circulation, vol. 99, no. 2, pp. 237–242, 1999. View at Google Scholar · View at Scopus
  43. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D'Agostino, and P. W. F. Wilson, “C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study,” Circulation, vol. 110, no. 4, pp. 380–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. P. W. F. Wilson, B. H. Nam, M. Pencina, R. B. D'Agostino, E. J. Benjamin, and C. J. O'Donnell, “C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study,” Archives of Internal Medicine, vol. 165, no. 21, pp. 2473–2478, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Li and C. H. Fang, “C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases,” Medical Hypotheses, vol. 62, no. 4, pp. 499–506, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. L. J. Powell, “C-reactive protein—a review,” The American journal of medical technology, vol. 45, no. 2, pp. 138–142, 1979. View at Google Scholar · View at Scopus
  48. K. Matsushita, H. Yatsuya, K. Tamakoshi et al., “High-sensitivity C-reactive protein is quite low in Japanese men at high coronary risk,” Circulation Journal, vol. 71, no. 6, pp. 820–825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Kosuge, T. Ebina, T. Ishikawa et al., “Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes,” Circulation Journal, vol. 71, no. 2, pp. 186–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. R. L. Meek, S. Urieli-Shoval, and E. P. Benditt, “Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3186–3190, 1994. View at Google Scholar · View at Scopus
  51. V. L. King, J. Thompson, and L. R. Tannock, “Serum amyloid A in atherosclerosis,” Current Opinion in Lipidology, vol. 22, no. 4, pp. 302–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Badolato, J. M. Wang, W. J. Murphy et al., “Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 203–209, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. R. O'Hara, E. P. Murphy, A. S. Whitehead, O. FitzGerald, and B. Bresnihan, “Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1788–1799, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Song, Y. Shen, E. Yamen et al., “Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes,” Atherosclerosis, vol. 202, no. 2, pp. 596–604, 2009. View at Google Scholar · View at Scopus
  55. H. Cai, C. Song, I. Endoh et al., “Serum amyloid A induces monocyte tissue factor,” Journal of Immunology, vol. 178, no. 3, pp. 1852–1860, 2007. View at Google Scholar · View at Scopus
  56. C. P. J. Maury, “Comparative study of serum amyloid A protein and C-reactive protein in disease,” Clinical Science, vol. 68, no. 2, pp. 233–238, 1985. View at Google Scholar · View at Scopus
  57. J. Wilkins, J. R. Gallimore, G. A. Tennent et al., “Rapid automated enzyme immunoassay of serum amyloid A,” Clinical Chemistry, vol. 40, no. 7, pp. 1284–1290, 1994. View at Google Scholar · View at Scopus
  58. T. Nakayama, S. Sonoda, T. Urano, T. Yamada, and M. Okada, “Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases,” Clinical Chemistry, vol. 39, no. 2, pp. 293–297, 1993. View at Google Scholar · View at Scopus
  59. J. M. Mayer, M. Raraty, J. Slavin et al., “Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis,” British Journal of Surgery, vol. 89, no. 2, pp. 163–171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Cunnane, S. Grehan, S. Geoghegan et al., “Serum amyloid A in the assessment of early inflammatory arthritis,” Journal of Rheumatology, vol. 27, no. 1, pp. 58–63, 2000. View at Google Scholar · View at Scopus
  61. M. T. Casl, G. Bulatovic, P. Orlic, and M. Sabljar-Matovinovic, “The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection,” Nephrology Dialysis Transplantation, vol. 10, no. 10, pp. 1901–1904, 1995. View at Google Scholar · View at Scopus
  62. T. Katayama, H. Nakashima, C. Takagi et al., “Prognostic value of serum amyloid a protein in patients with acute myocardial infarction,” Circulation Journal, vol. 69, no. 10, pp. 1186–1191, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina,” The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. T. W. Meade, W. R. North, R. Chakrabarti et al., “Haemostatic function and cardiovascular death: early results of a prospective study,” The Lancet, vol. 1, no. 8177, pp. 1050–1053, 1980. View at Google Scholar · View at Scopus
  65. W. Nieuwenhuizen, “Biochemistry and measurement of fibrinogen,” European Heart Journal, vol. 16, supplement, pp. 6–10, 1995. View at Google Scholar · View at Scopus
  66. R. F. Doolittle, “Fibrinogen and fibrin,” Scientific American, vol. 245, no. 6, pp. 126–152, 1981. View at Google Scholar · View at Scopus
  67. J. J. Stec, H. Silbershatz, G. H. Tofler et al., “Association of fibrinogen with cardiovascular risk factors and cardiovascluar disease the Framingham Offspring Population,” Circulation, vol. 102, no. 14, pp. 1634–1638, 2000. View at Google Scholar · View at Scopus
  68. M. J. Davies, “The contribution of thrombosis to the clinical expression of coronary atherosclerosis,” Thrombosis Research, vol. 82, no. 1, pp. 1–32, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Eriksson, N. Egberg, S. Wamala, K. Orth-Gomér, M. A. Mittleman, and K. Schenck-Gustafsson, “Relationship between plasma fibrinogen and coronary heart disease in women,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 1, pp. 67–72, 1999. View at Google Scholar · View at Scopus
  70. S. G. Thompson, J. Kienast, S. D. M. Pyke et al., “Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris,” The New England Journal of Medicine, vol. 332, no. 10, pp. 635–641, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Fogari, A. Zoppi, G. Marasi, A. Vanasia, and G. Villa, “Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men,” Journal of Cardiovascular Risk, vol. 1, no. 4, pp. 341–345, 1994. View at Google Scholar · View at Scopus
  72. H. H. Ditschuneit, M. Flechtner-Mors, and G. Adler, “Fibrinogen in obesity before and after weight reduction,” Obesity Research, vol. 3, no. 1, pp. 43–48, 1995. View at Google Scholar · View at Scopus
  73. J. Heinrich, L. Balleisen, H. Schulte, G. Assmann, and J. Van de Loo, “Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men,” Arteriosclerosis and Thrombosis, vol. 14, no. 1, pp. 54–59, 1994. View at Google Scholar · View at Scopus
  74. E. Vanninen, J. Laitinen, and M. Uusitupa, “Physical activity and fibrinogen concentration in newly diagnosed NIDDM,” Diabetes Care, vol. 17, no. 9, pp. 1031–1038, 1994. View at Google Scholar · View at Scopus
  75. M. Gil, M. Zarebiński, and J. Adamus, “Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina,” International Journal of Cardiology, vol. 83, no. 1, pp. 43–46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Shi, Y. Wu, C. Bian, W. Zhang, J. Yang, and G. Xu, “Predictive value of plasma fibrinogen levels: in patients admitted for acute coronary syndrome,” Texas Heart Institute Journal, vol. 37, no. 2, pp. 178–183, 2010. View at Google Scholar · View at Scopus
  77. J. S. Rana, S. M. Boekholdt, P. M. Ridker et al., “Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study,” Journal of Internal Medicine, vol. 262, no. 6, pp. 678–689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. C. S. Keefer and W. H. Resnik, “Angina pectoris: a syndrome caused by anoxemia of the myocardium,” Archives of Internal Medicine, vol. 41, pp. 769–807, 1928. View at Google Scholar
  79. J. B. Zalokar, J. L. Richard, and J. R. Claude, “Leukocyte count, smoking, and myocardial infarction,” The New England Journal of Medicine, vol. 304, no. 8, pp. 465–468, 1981. View at Google Scholar · View at Scopus
  80. R. H. Grimm Jr., J. D. Neaton, and W. Ludwig, “Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality,” Journal of the American Medical Association, vol. 254, no. 14, pp. 1932–1937, 1985. View at Publisher · View at Google Scholar · View at Scopus
  81. A. N. Phillips, J. D. Neaton, D. G. Cook, R. H. Grimm, and A. G. Shaper, “Leukocyte count and risk of major coronary heart disease events,” American Journal of Epidemiology, vol. 136, no. 1, pp. 59–70, 1992. View at Google Scholar · View at Scopus
  82. W. B. Kannel, K. Anderson, and P. W. F. Wilson, “White blood cell count and cardiovascular disease: insights from the Framingham study,” Journal of the American Medical Association, vol. 267, no. 9, pp. 1253–1256, 1992. View at Publisher · View at Google Scholar · View at Scopus
  83. R. F. Gillum, D. D. Ingram, and D. M. Makuc, “White blood cell count, coronary heart disease, and death: the NHANES I epidemiologic follow-up study,” American Heart Journal, vol. 125, no. 3, pp. 855–863, 1993. View at Publisher · View at Google Scholar · View at Scopus
  84. A. R. Folsom, K. K. Wu, W. D. Rosamond, A. R. Sharrett, and L. E. Chambless, “Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study,” Circulation, vol. 96, no. 4, pp. 1102–1108, 1997. View at Google Scholar · View at Scopus
  85. C. D. Lee, A. R. Folsom, F. J. Nieto, L. E. Chambless, E. Shahar, and D. A. Wolfe, “White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis Risk in Communities Study,” American Journal of Epidemiology, vol. 154, no. 8, pp. 758–764, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. D. W. Brown, W. H. Giles, and J. B. Croft, “White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort,” Journal of Clinical Epidemiology, vol. 54, no. 3, pp. 316–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Madjid, I. Awan, J. T. Willerson, and S. W. Casscells, “Leukocyte count and coronary heart disease: implications for risk assessment,” Journal of the American College of Cardiology, vol. 44, no. 10, pp. 1945–1956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. R. C. Schlant, S. Forman, J. Stamler, and P. L. Canner, “The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project,” Circulation, vol. 66, no. 2, pp. 401–414, 1982. View at Google Scholar · View at Scopus
  89. R. Hajj-Ali, W. Zareba, R. Ezzeddine, and A. J. Moss, “Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction,” American Journal of Cardiology, vol. 88, no. 11, pp. 1221–1224, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. G. Schillaci, M. Pirro, G. Pucci et al., “Prognostic value of elevated white blood cell count in hypertension,” American Journal of Hypertension, vol. 20, no. 4, pp. 364–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. R. H. Orakzai, S. H. Orakzai, K. Nasir et al., “Association of white blood cell count with systolic blood pressure within the normotensive range,” Journal of Human Hypertension, vol. 20, no. 5, pp. 341–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. G. D. Friedman, J. V. Selby, and C. P. Quesenberry Jr., “The leukocyte count: a predictor of hypertension,” Journal of Clinical Epidemiology, vol. 43, no. 9, pp. 907–911, 1990. View at Publisher · View at Google Scholar · View at Scopus
  93. O. Kuchel, “The autonomic nervous system and blood pressure regulation in human hypertension,” in Hypertension: Physiopathology and Treatment, J. Genest, O. Kuchal, P. Hamet, and M. Cantin, Eds., pp. 140–160, McGraw- Hill, New York, NY, USA, 2nd edition, 1983. View at Google Scholar
  94. S. Umemoto, N. Suzuki, K. Fujii et al., “Eosinophil counts and plasma fibrinogen in patients with vasospastic angina pectoris,” American Journal of Cardiology, vol. 85, no. 6, pp. 715–719, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. L. M. Biasucci, G. D'Onofrio, G. Liuzzo et al., “Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia,” Journal of the American College of Cardiology, vol. 27, no. 3, pp. 611–616, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Pontremoli, F. Salamino, B. Sparatore et al., “Enhanced activation of the respiratory burst oxidase in neutrophils from hypertensive patients,” Biochemical and Biophysical Research Communications, vol. 158, no. 3, pp. 966–972, 1989. View at Google Scholar · View at Scopus
  97. P. S. Tsao, X. L. Ma, and A. M. Lefer, “Activated neutrophils aggravate endothelial dysfunction after reperfusion of the ischemic feline myocardium,” American Heart Journal, vol. 123, no. 6, pp. 1464–1471, 1992. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Siminiak, N. A. Flores, and D. J. Sheridan, “Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury,” European Heart Journal, vol. 16, no. 2, pp. 160–170, 1995. View at Google Scholar · View at Scopus
  99. E. H. Ohlstein and A. J. Nichols, “Rabbit polymorphonuclear neutrophils elicit endothelium-dependent contraction in vascular smooth muscle,” Circulation Research, vol. 65, no. 4, pp. 917–924, 1989. View at Google Scholar · View at Scopus
  100. A. R. Whorton, M. E. Montgomery, and R. S. Kent, “Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells,” Journal of Clinical Investigation, vol. 76, no. 1, pp. 295–302, 1985. View at Google Scholar · View at Scopus
  101. Z. S. Katusic and P. M. Vanhoutte, “Superoxide anion is an endothelium-derived contracting factor,” American Journal of Physiology, vol. 257, no. 1, pp. H33–H37, 1989. View at Google Scholar · View at Scopus
  102. A. D. Hingorani, J. Cross, R. K. Kharbanda et al., “Acute systemic inflammation impairs endothelium-dependent dilatation in humans,” Circulation, vol. 102, no. 9, pp. 994–999, 2000. View at Google Scholar · View at Scopus
  103. J. Mehta, J. Dinerman, P. Mehta et al., “Neutrophil function in ishemic heart disease,” Circulation, vol. 79, no. 3, pp. 549–556, 1989. View at Google Scholar · View at Scopus
  104. I. Ott, F. J. Neumann, M. Gawaz, M. Schmitt, and A. Schömig, “Increased neutrophil-platelet adhesion in patients with unstable angina,” Circulation, vol. 94, no. 6, pp. 1239–1246, 1996. View at Google Scholar · View at Scopus
  105. S. R. Ommen, R. J. Gibbons, D. O. Hodge, and S. P. Thomson, “Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease,” American Journal of Cardiology, vol. 79, no. 6, pp. 812–814, 1997. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Fichtlscherer, M. Kaszkin, S. Breuer, S. Dimmeler, and A. M. Zeiher, “Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease,” Clinical Science, vol. 106, no. 5, pp. 511–517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Hurt-Camejo, G. Camejo, H. Peilot, K. Öörni, and P. Kovanen, “Phospholipase A2 in vascular disease,” Circulation Research, vol. 89, no. 4, pp. 298–304, 2001. View at Google Scholar · View at Scopus
  108. H. W. M. Niessen, P. A. J. Krijnen, C. A. Visser, C. J. L. M. Meijer, and C. E. Hack, “Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?” Cardiovascular Research, vol. 60, no. 1, pp. 68–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Menschikowski, A. Rosner-Schiering, R. Eckey, E. Mueller, R. Koch, and W. Jaross, “Expression of secretory group IIA phospholipase A2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 751–762, 2000. View at Google Scholar · View at Scopus
  110. E. Hurt-Camejo, S. Andersen, R. Standal et al., “Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 2, pp. 300–309, 1997. View at Google Scholar · View at Scopus
  111. M. Romano, E. Romano, S. Björkerud, and E. Hurt-Camejo, “Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 519–525, 1998. View at Google Scholar · View at Scopus
  112. G. C. Beck, B. A. Yard, J. Schulte et al., “Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium,” Biochemical and Biophysical Research Communications, vol. 300, no. 3, pp. 731–737, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Kugiyama, Y. Ota, K. Takazoe et al., “Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease,” Circulation, vol. 100, no. 12, pp. 1280–1284, 1999. View at Google Scholar · View at Scopus
  114. W. Koenig, C. Y. Vossen, Z. Mallat, H. Brenner, J. Benessiano, and D. Rothenbacher, “Association between type II secretory phospholipase A 2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease,” European Heart Journal, vol. 30, no. 22, pp. 2742–2748, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. C. Raguenes-Nicol, F. Russo-Marie, G. Domage et al., “Anti-inflammatory mechanism of alminoprofen: action on the phospholipid metabolism pathway,” Biochemical Pharmacology, vol. 57, no. 4, pp. 433–443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  116. M. J. B. M. Vervoordeldonk, I. M. Pineda Torra, A. J. Aarsman, and H. Van Den Bosch, “Aspirin inhibits expression of the interleukin-1β-inducible group II phospholipase A2,” FEBS Letters, vol. 397, no. 1, pp. 108–112, 1996. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Dua and W. Cho, “Inhibition of human secretory class II phospholipase A2 by heparin,” European Journal of Biochemistry, vol. 221, no. 1, pp. 481–490, 1994. View at Google Scholar · View at Scopus
  118. W. Pruzanski, E. Stefanski, P. Vadas, T. F. McNamara, N. Ramamurthy, and L. M. Golub, “Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2,” Journal of Rheumatology, vol. 25, no. 9, pp. 1807–1812, 1998. View at Google Scholar · View at Scopus
  119. O. Wiklund, L. Mattsson-Hultén, E. Hurt-Camejo, and J. Oscarsson, “Effects of simvastatin and atorvastatin on inflammation markers in plasma,” Journal of Internal Medicine, vol. 251, no. 4, pp. 338–347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. X. Chen, T. O. Scholl, and T. P. Stein, “Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study,” Diabetes Care, vol. 29, no. 5, pp. 1077–1082, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. R. J. Wood, “The iron-heart disease connection: is it dead or just hiding?” Ageing Research Reviews, vol. 3, no. 3, pp. 355–367, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. M. C. Linder, K. J. Schaffer, M. Hazegh-Azam, C. Y. J. Zhou, T. N. Tran, and G. M. Nagel, “Serum ferritin: does it differ from tissue ferritin?” Journal of Gastroenterology and Hepatology, vol. 11, no. 11, pp. 1033–1036, 1996. View at Google Scholar · View at Scopus
  123. M. J. Hynes and M. Ó Coinceanainn, “Investigation of the release of iron from ferritin by naturally occurring antioxidants,” Journal of Inorganic Biochemistry, vol. 90, no. 1-2, pp. 18–21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. K. D. Welch, C. A. Reilly, and S. D. Aust, “The role of cysteine residues in the oxidation of ferritin,” Free Radical Biology and Medicine, vol. 33, no. 3, pp. 399–408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Rudeck, T. Volk, N. Sitte, and T. Grüne, “Ferritin oxidation in vitro: implication of iron release and degradation by the 20s proteasome,” IUBMB Life, vol. 49, no. 5, pp. 451–456, 2000. View at Google Scholar · View at Scopus
  126. T. N. Tran, S. K. Eubanks, K. J. Schaffer, C. Y. J. Zhou, and M. C. Linder, “Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron,” Blood, vol. 90, no. 12, pp. 4979–4986, 1997. View at Google Scholar · View at Scopus
  127. C. Beerenhout, O. Bekers, J. P. Kooman, F. M. Van Der Sande, and K. M. L. Leunissen, “A comparison between the soluble transferrin receptor, transferrin saturation and serum ferritin as markers of iron state in hemodialysis patients,” Nephron, vol. 92, no. 1, pp. 32–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, “Elevated C-reactive protein levels in overweight and obese adults,” Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  129. D. J. Fleming, P. F. Jacques, J. M. Massaro, R. B. D'Agostino Sr., P. W. F. Wilson, and R. J. Wood, “Aspirin intake and the use of serum ferritin as a measure of iron status,” American Journal of Clinical Nutrition, vol. 74, no. 2, pp. 219–226, 2001. View at Google Scholar · View at Scopus
  130. K. C. Sung, J. H. Kang, and H. S. Shin, “Relationship of Cardiovascular Risk Factors and Serum Ferritin with C-reactive Protein,” Archives of Medical Research, vol. 38, no. 1, pp. 121–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. J. T. Salonen, K. Nyyssonen, H. Korpela, J. Tuomilehto, R. Seppanen, and R. Salonen, “High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men,” Circulation, vol. 86, no. 3, pp. 803–811, 1992. View at Google Scholar · View at Scopus
  132. S. Kiechl, J. Willeit, G. Egger, W. Poewe, and F. Oberhollenzer, “Body iron stores and the risk of carotid atherosclerosis: prospective results from the bruneck study,” Circulation, vol. 96, no. 10, pp. 3300–3307, 1997. View at Google Scholar · View at Scopus
  133. P. Galan, N. Noisette, C. Estaquio et al., “Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Minéraux AntioXydants) cohort,” Public Health Nutrition, vol. 9, no. 1, pp. 70–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. C. T. Sempos, A. C. Looker, R. F. Gillum, D. L. McGee, C. V. Vuong, and C. L. Johnson, “Serum ferritin and death from all causes and cardiovascular disease: the NHANES II mortality study,” Annals of Epidemiology, vol. 10, no. 7, pp. 441–448, 2000. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Dominguez-Rodriguez, Tome M. Carrillo-Perez, C. Hernandez-Garcia et al., “Serum ferritin and acute coronary syndrome: a strong prognostic factor?” International Journal of Cardiology, vol. 152, no. 1, pp. 129–130, 2011. View at Google Scholar
  136. Y. Fan, J. Wang, L. Wei, B. He, C. Wang, and Binyao Wang, “Iron deficiency activates pro-inflammatory signaling in macrophages and foam cells via the p38 MAPK-NF-κB pathway,” International Journal of Cardiology, vol. 152, no. 1, pp. 49–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. H. L. Viener and A. P. Levy, “Haptoglobin genotype and the iron hypothesis of atherosclerosis,” Atherosclerosis, vol. 216, no. 1, pp. 17–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. B. H. Bowman and A. Kurosky, “Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation,” Advances in Human Genetics, vol. 12, pp. 189–453, 1982. View at Google Scholar · View at Scopus
  139. A. P. Levy, R. Asleh, S. Blum et al., “Haptoglobin: basic and clinical aspects,” Antioxidants and Redox Signaling, vol. 12, no. 2, pp. 293–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Kristiansen, J. H. Graversen, C. Jacobsen et al., “Identification of the haemoglobin scavenger receptor,” Nature, vol. 409, no. 6817, pp. 198–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. J. H. Graversen, M. Madsen, and S. K. Moestrup, “CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 4, pp. 309–314, 2002. View at Publisher · View at Google Scholar · View at Scopus
  142. R. Asleh, J. Guetta, S. Kalet-Litman, R. Miller-Lotan, and A. P. Levy, “Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo,” Circulation Research, vol. 96, no. 4, pp. 435–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. F. S. Boretti, P. W. Buehler, F. D'Agnillo et al., “Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs,” Journal of Clinical Investigation, vol. 119, no. 8, pp. 2271–2280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  144. J. H. Crawford, T. S. Isbell, Z. Huang et al., “Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation,” Blood, vol. 107, no. 2, pp. 566–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  145. G. J. Kato, “Haptoglobin halts hemoglobin's havoc,” Journal of Clinical Investigation, vol. 119, no. 8, pp. 2140–2142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Blum, M. Vardi, J. B. Brown et al., “Vitamin e reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype,” Pharmacogenomics, vol. 11, no. 5, pp. 675–684, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Roguin, W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A. P. Levy, “Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes,” Diabetes Care, vol. 26, no. 9, pp. 2628–2631, 2003. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Suleiman, D. Aronson, R. Asleh et al., “Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction,” Diabetes, vol. 54, no. 9, pp. 2802–2806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  150. U. Milman, S. Blum, C. Shapira et al., “Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 341–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. T. Costacou, R. E. Ferrell, and T. J. Orchard, “Haptoglobin genotype a determinant of cardiovascular complication risk in type 1 diabetes,” Diabetes, vol. 57, no. 6, pp. 1702–1706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. F. M. Nakhoul, R. Zoabi, Y. Kanter et al., “Haptoglobin phenotype and diabetic nephropathy,” Diabetologia, vol. 44, no. 5, pp. 602–604, 2001. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Roguin, I. Hochberg, E. Nikolsky et al., “Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 87, no. 3, pp. 330–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  155. D. D. Bacquer, G. Backer, M. D. Langlois, J. Delanghe, H. Kesteloot, and M. Kornitzer, “Haptoglobin polymorphism as a risk factor for coronary heart disease mortality,” Atherosclerosis, vol. 157, no. 1, pp. 161–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  156. P. L. Fox, B. Mazumder, E. Ehernwal et al., “Ceruplasmin and cardiovascular disease,” Free Radical Biology & Medicine, vol. 28, no. 12, pp. 1735–1744, 2000. View at Google Scholar
  157. L. Rydén, “Ceruloplasmin,” in Copper Proteins and Copper Enzymes, Volume III, R. Lontie, Ed., pp. 37–100, CRC Press, Boca Raton, Fla, USA, 1984. View at Google Scholar
  158. P. L. Fox, C. Mukhopadhyay, and E. Ehrenwald, “Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin,” Life Sciences, vol. 56, no. 21, pp. 1749–1758, 1995. View at Publisher · View at Google Scholar · View at Scopus
  159. E. Frieden and H. S. Hsieh, “The biological role of ceruloplasmin and its oxidase activity,” Advances in Experimental Medicine and Biology, vol. 74, pp. 505–529, 1976. View at Google Scholar · View at Scopus
  160. W. H. Tang, Y. Wu, S. J. Nicholls, and S. L. Hazen, “Serum Cp: independently predicts cardiovascular risk in stable cardiac patients,” Circulation, vol. 122, 2010, Meeting Abstract Supplement, abstract no. 18791. View at Google Scholar
  161. S. J. Adelstein, T. L. Coombs, and B. L. Vallee, “Metalloenzymes and myocardial infarction. I. The relation between serum copper and ceruloplasmin and its catalytic activity,” The New England Journal of Medicine, vol. 255, no. 3, pp. 105–109, 1956. View at Google Scholar · View at Scopus
  162. J. Bustamante, M. C. Martin, and J. Fernandez, “Zinc, copper and ceruloplasmin in arteriosclerosis,” Biomedicine Express, vol. 25, no. 7, pp. 244–245, 1976. View at Google Scholar · View at Scopus
  163. J. T. Powell, B. R. Muller, and R. M. Greenhalgh, “Acute phase proteins in patients with abdominal aortic aneurysms,” Journal of Cardiovascular Surgery, vol. 28, no. 5, pp. 528–530, 1987. View at Google Scholar · View at Scopus
  164. N. Jayakumari, V. Ambikakumari, K. G. Balakrishnan, and K. Subramonia Iyer, “Antioxidant status in relation to free radical production during stable and unstable anginal syndromes,” Atherosclerosis, vol. 94, no. 2-3, pp. 183–190, 1992. View at Publisher · View at Google Scholar · View at Scopus
  165. J. J. F. Belch, M. Chopra, S. Hutchison et al., “Free radical pathology in chronic arterial disease,” Free Radical Biology and Medicine, vol. 6, no. 4, pp. 375–378, 1989. View at Google Scholar · View at Scopus
  166. J. T. Salonen, R. Salonen, H. Korpela, S. Suntioinen, and J. Tuomilehto, “Serum copper and the risk of acute myocardial infarction: a prospective population study in men in Eastern Finland,” American Journal of Epidemiology, vol. 134, no. 3, pp. 268–276, 1991. View at Google Scholar · View at Scopus
  167. J. T. Salonen, R. Salonen, K. Seppänen, M. Kantola, S. Suntioinen, and H. Korpela, “Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis,” British Medical Journal, vol. 302, no. 6779, pp. 756–760, 1991. View at Google Scholar · View at Scopus
  168. J. Swain and J. M. C. Gutteridge, “Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material,” FEBS Letters, vol. 368, no. 3, pp. 513–515, 1995. View at Publisher · View at Google Scholar · View at Scopus
  169. C. Smith, M. J. Mitchinson, O. I. Aruoma, and B. Halliwell, “Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions,” Biochemical Journal, vol. 286, no. 3, pp. 901–905, 1992. View at Google Scholar · View at Scopus
  170. A. Ziakas, S. Gavrilidis, E. Souliou et al., “Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina,” Angiology, vol. 60, no. 1, pp. 50–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  171. N. Jayakumari, V. Ambikakumari, K. G. Balakrishnan, and K. Subramonia Iyer, “Antioxidant status in relation to free radical production during stable and unstable anginal syndromes,” Atherosclerosis, vol. 94, no. 2-3, pp. 183–190, 1992. View at Publisher · View at Google Scholar · View at Scopus
  172. J. T. Salonen, R. Salonen, K. Seppanen, M. Kantola, S. Suntioinen, and H. Korpela, “Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis,” British Medical Journal, vol. 302, no. 6779, pp. 756–760, 1991. View at Google Scholar · View at Scopus
  173. M. J. Saraiva, “Transthyretin amyloidosis: a tale of weak interactions,” FEBS Letters, vol. 498, no. 2-3, pp. 201–203, 2001. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Mezzetti, M. D. Guglielmi, S. D. Pierdomenico et al., “Increased systemic oxidative stress after elective endarterectomy—relation to vascular healing and remodeling,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 11, pp. 2659–2665, 1999. View at Google Scholar · View at Scopus
  175. A. G. Shaper, S. G. Wannamethee, and P. H. Whincup, “Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking,” Journal of Clinical Epidemiology, vol. 57, no. 2, pp. 195–202, 2004. View at Publisher · View at Google Scholar · View at Scopus
  176. L. H. Kuller, R. P. Tracy, J. Shaten, and E. N. Meilahn, “Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study,” American Journal of Epidemiology, vol. 144, no. 6, pp. 537–547, 1996. View at Google Scholar · View at Scopus
  177. J. Danesh, R. Collins, P. Appleby, and R. Peto, “Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies,” Journal of the American Medical Association, vol. 279, no. 18, pp. 1477–1482, 1998. View at Publisher · View at Google Scholar · View at Scopus
  178. R. F. Gillum, D. D. Ingram, and D. M. Makuc, “Relation between serum albumin concentration and stroke incidence and death: the NHANES I epidemiologic follow-up study,” American Journal of Epidemiology, vol. 140, no. 10, pp. 876–888, 1994. View at Google Scholar · View at Scopus
  179. P. S. Lim, Y. M. Cheng, and S. M. Yang, “Impairments of the biological properties of serum albumin in patients on haemodialysis,” Nephrology, vol. 12, no. 1, pp. 18–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. M. P. Weijenberg, E. J. M. Feskens, J. H. M. Souverijn, and D. Kromhout, “Serum albumin, coronary heart disease risk, and mortality in an elderly cohort,” Epidemiology, vol. 8, no. 1, pp. 87–92, 1997. View at Google Scholar · View at Scopus
  181. B. Halliwell and J. M. C. Gutteridge, “The antioxidants of human extracellular fluids,” Archives of Biochemistry and Biophysics, vol. 280, no. 1, pp. 1–8, 1990. View at Publisher · View at Google Scholar · View at Scopus
  182. L. H. Kuller, J. E. Eichner, T. J. Orchard, G. A. Grandits, L. McCallum, and R. P. Tracy, “The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial,” American Journal of Epidemiology, vol. 134, no. 11, pp. 1266–1277, 1991. View at Google Scholar · View at Scopus
  183. A. Phillips, A. G. Shaper, and P. H. Whincup, “Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes,” The Lancet, vol. 2, no. 8677, pp. 1434–1436, 1989. View at Google Scholar · View at Scopus
  184. L. Djoussé, K. J. Rothman, L. A. Cupples, D. Levy, and R. C. Ellison, “Serum albumin and risk of myocardial infarction and all-cause mortality in the framingham offspring study,” Circulation, vol. 106, no. 23, pp. 2919–2924, 2002. View at Publisher · View at Google Scholar · View at Scopus
  185. A.T. Høstmark, “Serum albumin and prevalence of coronary heart disease: a population-based, cross sectional study,” Norsk Epidemiologi, vol. 13, no. 1, pp. 107–113, 2003. View at Google Scholar
  186. V. Menon, X. Wang, T. Greene et al., “Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 44–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  187. D. Docci, R. Bilancioni, A. Buscaroli et al., “Elevated serum levels of C-reactive protein in hemodialysis patients,” Nephron, vol. 56, no. 4, pp. 364–367, 1990. View at Google Scholar · View at Scopus
  188. A. Fine, “Relevance of C-reactive protein levels in peritoneal dialysis patients,” Kidney International, vol. 61, no. 2, pp. 615–620, 2002. View at Publisher · View at Google Scholar · View at Scopus
  189. M. Haubitz, R. Brunkhorst, E. Wrenger, P. Froese, M. Schulze, and K. M. Koch, “Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy,” Peritoneal Dialysis International, vol. 16, no. 2, pp. 158–162, 1996. View at Google Scholar · View at Scopus
  190. T. A. Ikizler, R. L. Wingard, J. Harvell, Y. Shyr, and R. M. Hakim, “Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study,” Kidney International, vol. 55, no. 5, pp. 1945–1951, 1999. View at Publisher · View at Google Scholar · View at Scopus
  191. M. M. Avram, N. Mittman, L. Bonomini, J. Chattopadhyay, and P. Fein, “Markers for survival in dialysis: a seven-year prospective study,” American Journal of Kidney Diseases, vol. 26, no. 1, pp. 209–219, 1995. View at Google Scholar · View at Scopus
  192. R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, “Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 728–736, 1996. View at Google Scholar · View at Scopus
  193. R. M. Bologa, D. M. Levine, T. S. Parker et al., “Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 107–114, 1998. View at Google Scholar · View at Scopus
  194. A. R. Qureshi, A. Alvestrand, A. Danielsson et al., “Factors predicting malnutrition in hemodialysis patients: a cross- sectional study,” Kidney International, vol. 53, no. 3, pp. 773–782, 1998. View at Publisher · View at Google Scholar · View at Scopus
  195. G. A. Kaysen, J. A. Dubin, H. G. Müller, W. E. Mitch, and N. W. Levin, “Levels of α1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients,” Kidney International, vol. 60, no. 6, pp. 2360–2366, 2001. View at Publisher · View at Google Scholar · View at Scopus
  196. S. B. Kim, W. S. Yang, and J. S. Park, “Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients,” Peritoneal Dialysis International, vol. 19, no. 2, supplement, pp. S144–S149, 1999. View at Google Scholar · View at Scopus
  197. S. Y. Hong and D. H. Yang, “Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome,” Nephron, vol. 69, no. 2, pp. 125–130, 1995. View at Google Scholar · View at Scopus
  198. W. S. Yang, S. B. Kim, W. K. Min, S. Park, M. S. Lee, and J. S. Park, “Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 10, no. 9, pp. 1668–1671, 1995. View at Google Scholar · View at Scopus
  199. S. B. Kim, W. S. Yang, S. K. Lee, H. S. Chi, and J. S. Park, “Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients,” Nephrology Dialysis Transplantation, vol. 13, no. 8, pp. 2053–2058, 1998. View at Publisher · View at Google Scholar · View at Scopus
  200. P. Stenvinkel, L. Berglund, S. Ericsson, A. Alvestrand, B. Angelin, and M. Eriksson, “Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome,” European Journal of Clinical Investigation, vol. 27, no. 2, pp. 169–177, 1997. View at Google Scholar · View at Scopus
  201. W. S. Yang, S. B. Kim, W. K. Min, and J. S. Park, “Effect of increasing serum albumin onserum lipoprotein (a) concentration in patients on continuous ambulatory peritoneal dialysis,” American Journal of Kidney Diseases, vol. 30, pp. 507–513, 1997. View at Google Scholar
  202. J. H. Baxter, H. C. Goodman, and J. C. Allen, “Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis,” The Journal of Clinical Investigation, vol. 40, pp. 490–498, 1961. View at Google Scholar · View at Scopus
  203. J. C. Allen, J. H. Baxter, and H. C. Goodman, “Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis,” The Journal of Clinical Investigation, vol. 40, pp. 499–508, 1961. View at Google Scholar
  204. A. Kanfer, D. Kleinknecht, M. Broyer, and F. Josso, “Coagulation studies in 45 cases of nephrotic syndrome without uremia,” Thrombosis et Diathesis Haemorrhagica, vol. 24, no. 3, pp. 562–571, 1970. View at Google Scholar · View at Scopus
  205. K. J. Kim, W. S. Yang, S. B. Kim, S. K. Lee, and J. S. Park, “Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin,” Peritoneal Dialysis International, vol. 17, no. 2, pp. 157–161, 1997. View at Google Scholar · View at Scopus
  206. L. R. Pickart and M. M. Thaler, “Free fatty acids and albumin as mediators of thrombin stimulated fibrinogen synthesis,” American Journal of Physiology, vol. 230, no. 4, pp. 996–1002, 1976. View at Google Scholar · View at Scopus
  207. S. D. Johnson, C. E. Lucas, and S. J. Gerrick, “Altered coagulation after albumin supplements for treatment of oligemic shock,” Archives of Surgery, vol. 114, no. 4, pp. 379–383, 1979. View at Google Scholar · View at Scopus
  208. S. B. Kim, H. S. Chi, J. S. Park, C. D. Hong, and W. S. Yang, “Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients,” American Journal of Kidney Diseases, vol. 33, no. 2, pp. 312–317, 1999. View at Google Scholar · View at Scopus
  209. N. U. Bang, C. W. Trygstad, J. E. Schroeder, R. O. Heidenreich, and B. M. Csiscko, “Enhanced platelet function in glomerular renal disease,” The Journal of Laboratory and Clinical Medicine, vol. 81, no. 5, pp. 651–660, 1973. View at Google Scholar · View at Scopus
  210. K. A. Jorgensen and E. Stoffersen, “On the inhibitory effect of albumin on platelet aggregation,” Thrombosis Research, vol. 17, no. 1-2, pp. 13–18, 1980. View at Google Scholar · View at Scopus
  211. S. B. Kim, W. S. Yang, E. S. Kang, W. K. Min, and J. S. Park, “Lipoprotein (a) and Apo A phenotypes in patients with end-stage renal disease,” Peritoneal Dialysis International, vol. 17, pp. 236–242, 1997. View at Google Scholar
  212. A. J. Marcus, “Platelet activation,” in Atherosclerosis and Coronary Artery Disease, V. Fuster, R. Ross, and E. J. Topol, Eds., pp. 607–637, Raven, Philadelphia, Pa, USA, 1st edition, 1996. View at Google Scholar
  213. N. Yoshida and N. Aoki, “Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome,” Blood, vol. 52, no. 5, pp. 969–977, 1978. View at Google Scholar · View at Scopus
  214. G. Remuzzi, G. Mecca, D. Marchesi et al., “Platelet hyperaggregability and the nephrotic syndrome,” Thrombosis Research, vol. 16, no. 3-4, pp. 345–354, 1979. View at Google Scholar · View at Scopus
  215. A. Schieppati, P. Dodesini, A. Benigni et al., “The metabolism of arachidonic acid by platelets in nephrotic syndrome,” Kidney International, vol. 25, no. 4, pp. 671–676, 1984. View at Google Scholar · View at Scopus
  216. Z. Duniec and J. Robak, “Albumin is one of lipoxygenase inhibitors in serum,” Polish Journal of Pharmacology and Pharmacy, vol. 36, no. 5, pp. 465–471, 1984. View at Google Scholar · View at Scopus
  217. C. G. Groth, “The effect of infused albumin and Rheomacrodex on factors governing the flow properties of the human blood,” Acta Chirurgica Scandinavica, vol. 131, no. 4, pp. 290–297, 1966. View at Google Scholar · View at Scopus
  218. E. McGinley, G. D. O. Lowe, and M. Boulton Jones, “Blood viscosity and haemostasis in the nephrotic syndrome,” Thrombosis and Haemostasis, vol. 49, no. 3, pp. 155–157, 1983. View at Google Scholar · View at Scopus
  219. J. A. Joles, N. Willekes-Koolschijn, and H. A. Koomans, “Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine,” Kidney International, vol. 52, no. 3, pp. 761–770, 1997. View at Google Scholar · View at Scopus
  220. M. Feriani, P. L. Kimmel, J. Kurantsin-Mills, and J. P. Bosch, “Effect of renal replacement therapy on viscosity in end-stage renal disease patients,” American Journal of Kidney Diseases, vol. 19, no. 2, pp. 131–139, 1992. View at Google Scholar · View at Scopus
  221. M. P. Gordge, A. Patel, R. W. Faint, P. B. Rylance, and G. H. Neild, “Blood hyperviscosity and its relationship to progressive renal failure in patients with diabetic nephropathy,” Diabetic Medicine, vol. 7, no. 10, pp. 880–886, 1990. View at Google Scholar · View at Scopus
  222. A. Fleck and F. R. Path, “Acute phase response: implications for nutrition and recovery,” Nutrition, vol. 4, no. 2, pp. 109–117, 1988. View at Google Scholar · View at Scopus
  223. J. Y. Yeun and G. A. Kaysen, “Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients,” American Journal of Kidney Diseases, vol. 30, no. 6, pp. 923–927, 1997. View at Google Scholar · View at Scopus
  224. A. R. Folsom, J. Ma, J. H. Eckfeldt, F. J. Nieto, P. A. Metcalf, and R. W. Barnes, “Low serum albumin: association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness,” Annals of Epidemiology, vol. 5, no. 3, pp. 186–191, 1995. View at Publisher · View at Google Scholar · View at Scopus
  225. C. Rapezzi, C. C. Quarta, L. Riva et al., “Transthyretin-related amyloidoses and the heart: a clinical overview,” Nature Reviews Cardiology, vol. 7, no. 7, pp. 398–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  226. S. H. Ingbar, “Pre-albumin: a thyroxinebinding protein of human plasma,” Endocrinology, vol. 63, no. 2, pp. 256–259, 1958. View at Google Scholar · View at Scopus
  227. L. Rask, H. Anundi, and P. A. Peterson, “The primary structure of the human retinol-binding protein,” FEBS Letters, vol. 104, no. 1, pp. 55–58, 1979. View at Google Scholar · View at Scopus
  228. H. E. Schultze and J. F. Heremans, Molecular Biology of Human Proteins, Elsevier, London, UK, 1966.
  229. P. W. Dickson, A. R. Aldred, and P. D. Marley, “High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain,” Biochemical and Biophysical Research Communications, vol. 127, no. 3, pp. 890–895, 1985. View at Google Scholar · View at Scopus
  230. J. Robbins, “Thyroxine-binding proteins,” Progress in Clinical and Biological Research, vol. 5, pp. 331–355, 1976. View at Google Scholar · View at Scopus
  231. M. D. Benson and J. C. Kincaid, “The molecular biology and clinical features of amyloid neuropathy,” Muscle and Nerve, vol. 36, no. 4, pp. 411–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  232. P. Westermark, K. Sletten, B. Johansson, and G. G. Cornwell, “Fibril in senile systemic amyloidosis is derived from normal transthyretin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 7, pp. 2843–2845, 1990. View at Google Scholar · View at Scopus
  233. X. Hou, M. I. Aguilar, and D. H. Small, “Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration,” FEBS Journal, vol. 274, no. 7, pp. 1637–1650, 2007. View at Publisher · View at Google Scholar · View at Scopus
  234. Y. Ando, M. Nakamura, and S. Araki, “Transthyretin-related familial amyloidotic polyneuropathy,” Archives of Neurology, vol. 62, no. 7, pp. 1057–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  235. P. Westermark, M. D. Benson, J. N. Buxbaum et al., “A primer of amyloid nomenclature,” Amyloid, vol. 14, no. 3, pp. 179–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  236. R. H. Falk and S. W. Dubrey, “Amyloid heart disease,” Progress in Cardiovascular Diseases, vol. 52, no. 4, pp. 347–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  237. K. B. Shah, Y. Inoue, and M. R. Mehra, “Amyloidosis and the heart: a comprehensive review,” Archives of Internal Medicine, vol. 166, no. 17, pp. 1805–1813, 2006. View at Publisher · View at Google Scholar · View at Scopus
  238. C. Rapezzi, G. Merlini, C. C. Quarta et al., “Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types,” Circulation, vol. 120, no. 13, pp. 1203–1212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  239. J. Koyama, P. A. Ray-Sequin, R. Davidoff, and R. H. Falk, “Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis,” American Journal of Cardiology, vol. 89, no. 9, pp. 1067–1071, 2002. View at Publisher · View at Google Scholar · View at Scopus
  240. A. V. Kristen, J. B. Perz, S. O. Schonland et al., “Non-invasive predictors of survival in cardiac amyloidosis,” European Journal of Heart Failure, vol. 9, no. 6-7, pp. 617–624, 2007. View at Publisher · View at Google Scholar · View at Scopus
  241. M. R. Almeida, L. Gales, A. M. Damas, I. Cardoso, and M. J. Saraiva, “Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses,” Current Drug Targets, vol. 4, no. 5, pp. 587–596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  242. T. Mairal, J. Nieto, M. Pinto et al., “Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors,” PLoS ONE, vol. 4, no. 1, article e4124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  243. A. M. Johnson, G. Merlini, J. Sheldon, and K. Ichihara, “Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition—international federation of clinical chemistry and laboratory medicine (IFCC): IFCC scientific division committee on plasma proteins (C-PP),” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 3, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  244. P. Aisen, “Transferrin, the transferrin receptor, and the uptake of iron by cells,” Metal Ions in Biological Systems, vol. 35, pp. 585–631, 1998. View at Google Scholar · View at Scopus
  245. M. Ahmed, Detection of in vitro and in vivo oxidative modifications of ferritin and transferrin by mass spectrometry: hereditary hemochromatosis as a model, Ph.D. thesis, 2007.
  246. M. Thevis, R. R. Ogorzalek Loo, and J. A. Loo, “Mass spectrometric characterization of transferrins and their fragments derived by reduction of disulfide bonds,” Journal of the American Society for Mass Spectrometry, vol. 14, no. 6, pp. 635–647, 2003. View at Publisher · View at Google Scholar · View at Scopus
  247. R. Pakdaman, F. B. Abdallah, and J. M. El Hage Chahine, “Transferrin, is a mixed chelate-protein ternary complex involved in the mechanism of iron uptake by serum-transferrin in vitro?” Journal of Molecular Biology, vol. 293, no. 5, pp. 1273–1284, 1999. View at Publisher · View at Google Scholar · View at Scopus
  248. A. Van Campenhout, C. M. Van Campenhout, A. R. Lagrou, and B. Manuel-Y-Keenoy, “Transferrin modifications and lipid peroxidation: implications in diabetes mellitus,” Free Radical Research, vol. 37, no. 10, pp. 1069–1077, 2003. View at Publisher · View at Google Scholar · View at Scopus
  249. J. K. Brieland and J. C. Fantone, “Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: effect of pH and iron saturation,” Archives of Biochemistry and Biophysics, vol. 284, no. 1, pp. 78–83, 1991. View at Publisher · View at Google Scholar · View at Scopus
  250. M. Kar and A. S. Chakraborti, “Release of iron from haemoglobin—a possible source of free radicals in diabetes mellitus,” Indian Journal of Experimental Biology, vol. 37, no. 2, pp. 190–192, 1999. View at Google Scholar · View at Scopus
  251. P. Martin, C. Walton, C. Chapman, H. J. Bodansky, and M. H. Stickland, “Increased urinary excretion of transferrin in children with Type 1 diabetes mellitus,” Diabetic Medicine, vol. 7, no. 1, pp. 35–40, 1990. View at Google Scholar · View at Scopus
  252. M. J. O'Donnell, P. Martin, C. M. Florkowski et al., “Urinary transferrin excretion in Type 1 (insulin-dependent) diabetes mellitus,” Diabetic Medicine, vol. 8, no. 7, pp. 657–661, 1991. View at Google Scholar · View at Scopus
  253. C. K. Cheung, C. S. Cockram, V. T. F. Yeung, and R. Swaminathan, “Urinary excretion of transferrin by non-insulin-dependent diabetics: a marker for early complications?” Clinical Chemistry, vol. 35, no. 8, pp. 1672–1674, 1989. View at Google Scholar · View at Scopus
  254. C. P. McCormick, J. C. Konen, and Z. K. Shihabi, “Microtransferrinuria and microalbuminuria: I. In the diabetic human,” Clinical Physiology and Biochemistry, vol. 8, no. 2, pp. 53–58, 1990. View at Google Scholar · View at Scopus
  255. A. M. Bernard, A. A. Amor, J. Goemaere-Vanneste et al., “Microtransferrinuria is a more sensitive indicator of early glomerular damage in diabetes than microalbuminuria,” Clinical Chemistry, vol. 34, no. 9, pp. 1920–1921, 1988. View at Google Scholar · View at Scopus
  256. G. Cartei, D. Causarano, and R. Naccarato, “Transferrin behaviour in primary haemochromatosis,” Experientia, vol. 31, no. 3, pp. 373–375, 1975. View at Google Scholar · View at Scopus
  257. R. G. Batey, P. L. C. Fong, S. Shamir, and S. Sherlock, “A non-transferrin-bound serum iron in idiopathic hemochromatosis,” Digestive Diseases and Sciences, vol. 25, no. 5, pp. 340–346, 1980. View at Google Scholar · View at Scopus